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Aims Cyclin-dependent kinase inhibitors (CDKIs) play a critical role in negatively regulating the
proliferation of cardiomyocytes, although their role in cardiac differentiation remains largely undeter-
mined. We have shown that the most prominent CDKI in Xenopus, p27
Xic1(Xic1), plays a role in neuronal
and myotome differentiation beyond its ability to arrest the cell cycle. Thus, we investigated whether it
plays a similar role in cardiomyocyte differentiation.
Methods and results Xenopus laevis embryos were sectioned, and whole-mount antibody staining and
immunoﬂuorescence studies were carried out to determine the total number and percentage of differ-
entiated cardiomyocytes in mitosis. Capped RNA and/or translation-blocking Xic1 morpholino antisense
oligonucleotides (Xic1Mo) were microinjected into embryos, and their role on cardiac differentiation
was assessed by in situ hybridization and/or PCR. We show that cell-cycling post-gastrulation is not
essential for cardiac differentiation in Xenopus embryos, and conversely that some cells can express
markers of cardiac differentiation even when still in cycle. A targeted knock-down of Xic1 protein by
Xic1Mo microinjection decreases the expression of markers of cardiac differentiation, which can be
partially rescued by co-injection of full-length Xic1 RNA, demonstrating that Xic1 is essential for
heart formation. Furthermore, using deleted and mutant forms of Xic1, we show that neither its
abilities to inhibit the cell cycle nor the great majority of CDK kinase activity are essential for
Xic1’s function in cardiomyocyte differentiation, an activity that resides in the N-terminus of the
molecule.
Conclusion Altogether, our results demonstrate that the CDKI Xic1 is required in Xenopus cardiac differ-
entiation, and that this function is localized at its N-terminus, but it is distinct from its ability to arrest
the cell cycle and inhibit overall CDK kinase activity. Hence, these results suggest that CDKIs play an
important direct role in driving cardiomyocyte differentiation in addition to cell-cycle regulation.
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1. Introduction
The adult mammalian heart is generally considered a
terminally differentiated organ due to the absence of a
signiﬁcant regenerative ability, following incidences such
as ischaemic attack,
1,2 the major cause of morbidity and
mortality in the Western world. It has been argued that
the acquired specialization of the differentiated adult
cardiomyocytes renders the majority of them incapable
of proliferation, whereas a number of studies have
demonstrated that the embryonic cardiomyocytes have con-
siderable ability to divide.
2 In the mammalian heart, this
gradual developmental loss of cardiomyocyte proliferative
capacity, leading to a transition from hyperplastic to hyper-
trophic growth, has been attributed to a block in the cell
cycle with the majority of adult cardiomyocytes blocked in
the G0/G1 phase of the cell cycle.
3 It has been demonstrated
that the expression of negative regulators of cell cycle,
and in particular the cyclin-dependent kinase inhibitors
(CDKIs) p21
Cip1 and p27
Kip1 signiﬁcantly increases during
rat myocyte development.
4,5 Recently, it has become clear
that CDKIs, while playing a crucial role in cell-cycle exit in
multiple tissues of the developing organism, may also play
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above their ability to regulate cell division.
6 In particular,
CDKIs have been shown to play roles beyond the cell cycle
during neuronal differentiation.
7,8 A cell-cycle-independent
role has been conﬁrmed by studies of mammalian p27
Kip1 in
the developing mouse cerebral cortex. p27
Kip1 promotes
both differentiation and radial migration of cortical projec-
tion neurons and both these functions are independent of
its ability to regulate the cell cycle.
9 Although it is generally
accepted that there is an inverse relationship between
proliferation and differentiation, and molecules that induce
cell-cycle exit promote differentiation,
10 the processes of
cardiac differentiation and cell-cycle withdrawal have
generally been investigated in isolation, and the links
between these processes have not been fully elucidated.
Thus, the identiﬁcation of molecules that might play a
pivotal role in the decision to proliferate or differentiate is
crucial for a clearer understanding of cardiac development.
Here, we investigate the role of cell-cycle exit and CDKI
function in the development of Xenopus embryonic heart,
showing that by stage-29/30, when the heart can be distin-
guished morphologically, the vast majority of the cardiomyo-
cytes have exited the cell cycle. However, a small proportion
(1.5%) remains cycling even up to stage-41. By blocking cell
division from the gastrula stage, we show that cell prolifer-
ation is not essential for differentiation of cardiomyocytes,
and the resulting heart remains essentially normal in size,
as determined by the expression of markers of cardiac
differentiation. The CDKI Xic1 is expressed in the developing
heart and while overexpression of Xic1 has little effect,
depletion of Xic1 protein using antisense-morpholino-
oligonucleotides (Mo) leads to a substantial reduction in the
expression of markers of cardiac differentiation. This is due
to decrease in the number of differentiated cardiomyocytes,
resulting in a reduction in heart size, an effect that can be
rescued by restoring Xic1 protein. We further demonstrate
that Xic1 is required at later stages of cardiac differentiation.
Signiﬁcantly, the activity of Xic1 required for cardiac differ-
entiation is localized within its N-terminus and is distinct
from Xic1’s CDK inhibitory activity.
2. Materials and methods
2.1 Xenopus embryos
Xenopus laevis embryos were injected by standard methods using
either b-galactosidase mRNA (500 pg injected/embryo), or Biotin-
Dextran (70 kDa, 10 ng injected/embryo) developed with
ExtrAvidin-alkaline phosphatase (Sigma) and BCIP, as lineage
tracers. Only embryos expressing the lineage tracers in the appro-
priately targeted regions were analysed further. The investigation
conforms with the Guide for the Care and Use of Laboratory
Animals published by the US National Institutes of Health (NIH Pub-
lication No. 85–23, revised 1996).
2.2 mRNA injection and morpholinos
Xic1 morpholino (Xic1Mo) previously showed to block Xic1 trans-
lation
8 and a new control morpholino (CTRMo) with the ﬁve-
nucleotide substitutions were used (Supplementary material
online, Figure S1A). Capped RNAs were synthesized in vitro using
the SP6 Message Machine kit (Ambion) from nuc-b-gal (500 pg),
11
full-length WT-Xic1, 30 pg; CT-Xic1, 30 pg; and Xic1(35–96), 30 pg;
NT-Xic1, 15 pg
12 (Supplementary material online, Figure S2). Xic1
mRNA not targeted by Xic1Mo (FL-Xic1, NT-Xic1, and Xic1
CK-) used
for rescuing experiments had eight translationally silent nucleotide
substitutions (underlined), 50-AUGGCUGCAUUUCAUAUAGCGUU
AC-30, (Supplementary material online, Figures S1B and S2).
2.3 Reverse transcriptase–PCR
Total RNA was isolated from three whole embryos, per stage and
condition, using the RNeasy kit (Qiagen) and treated with DNaseI
before reverse transcription using 100 ng of RNA/reaction
(SuperscriptIII-RT, Invitrogen). Two microlitre of the synthesized
cDNA was then used as a template in a 20 mL PCR reaction incorpor-
ating
32P-dATP.
13 The optimum cycle number for each primer
pair was determined as the cycle number at the linear range of a
standard curve, constructed using a range of cDNA dilutions
at different cycle numbers. xODC, 558C, 20-cycles
14 also used
for qPCR; p27Xic1, 558C, 22-cycles;
8 cardiac Troponin I (TIc)-F:
50-TCGGTCCTATGCCACAGAACCAC-30; TIc-R: 50-TTTTGAA
CTTGCCACGGAGG-30;6 3 8C/28-cycles. xMHCa,6 6 8C/28-cycles and
xNkx2.5, 598C/30-cycles.
15 xMLC1v-F: 50-CCATGCTCCAACACATTTCC
A-30; xMLC1v-R: 50-CAGCTCCCATTACCGTACCATT-30; xMLC
1v-TaqmanTM probe: 50-FAM-ACATACGAAGACTTTGTTGAAGGGCTGC
-30-BHQ1, extension/acquisition: 608C/1 min.
2.4 Whole-mount in situ hybridization and antibody
staining
Linearized plasmids from xTIc (HindIII/T7), xNkx2.5 (EcoR1/T7),
xNkx2.10 (Not1/T7), and p27
Xic1 (BamH1/T7) were used to generate
digoxigenin-11-UTP-labelled (Boehringer Mannheim) antisense RNA
probes. Whole-mount in situ hybridization (ISH) was carried out
as described previously
16 with BM-purple substrate. Whole-mount
antibody staining for a-phospho-histone H3 (phH3) (1:500, TCS
Biologicals) was performed as described previously.
16
2.5 Immunoﬂuorescence
E m b r y o sw e r eﬁ x e di n4 %p a r a f o r m a l d e h y d ei nP B Sf o r4 5 m i na n d
embedded in O.C.T. (Sakura Finetek, Tissue-Tek). Consecutive 10 mm
cryostat sections were immunostained using standard methods with
mouse a-Tropomyosin (CH1, 1:500; Developmental Studies Hybridoma
Bank), or a-phH3. Secondary antibodies were Alexa Fluor 546-coupled
a-mouse or Alexa Fluor 488-coupled a-rabbit.
All statistical analyses were performed using one-way analysis of
variance and Bonferonni t-test.
3. Results
3.1 Terminally differentiated embryonic Xenopus
cardiomyocytes maintain proliferative capacity
To investigate proliferative capacity of Xenopus hearts
during embryonic development, we determined the total
number and percentage of cardiomyocytes that were prolif-
erating by immunostaining embryo sections at various stages
expressing Tropomyosin, a marker of heart differentiation
along with a marker for mitotic cells, phosphorylated
histone H3 (phH3) (Figure 1A). The total number of cardio-
myocytes in the heart gradually increased from
stages-29/30 to -39 but no further signiﬁcant change
occurred from stages-39 to -41 (Figure 1B). Statistical
analyses conﬁrmed a signiﬁcant increase in total number
of myocytes when comparing stages-37/8 to -33/4 and all
earlier stages (Figure 1B, P , 0.025) with a doubling
in myocyte number between stage-32 (509+45) and
stage-37/8 (1164+184). We observed a signiﬁcant increase
in myocyte number from stage-39, when compared to all
earlier stages (Figure 1B, P , 0.05).
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(e.g. Figure 1A), indicating that the structural genes are
expressed in Xenopus cardiomyocytes that have not stably
exited the cell cycle. Indeed, at all stages of heart develop-
ment studied, we observed a small percentage of cells
co-expressing both phH3 and Tropomyosin (Figure 1C),
with this increasing signiﬁcantly at stages-31 (P , 0.04,
Figure 1C). Thus, while the vast majority of differentiated
cardiomyocytes are not proliferating, a small percentage
remains in cycle.
3.2 Xenopus cardiac differentiation can occur
normally when the cell cycle is inhibited
Here we investigated the contribution of cell proliferation in
determining the size of the linear heart-tube formed. In
addition, we investigated the extent to which cells are
able to respond to cardiac differentiation cues if cell
cycling is prevented in post-gastrulating Xenopus embryos.
It has previously been reported that blocking cell cycling
in Xenopus embryos just post-gastrulation, using the DNA
replication inhibitors, Hydroxyurea and Aphidicolin (HUA),
results in no gross phenotypic abnormalities, although
their cells are considerably larger.
17 We incubated stage-13
embryos in HUA, and investigated the effects on formation
and differentiation of the heart at both the cardiac plate
and linear heart-tube stages (stages-29/30 and 33/4,
respectively). phH3 staining was performed at stage-29/30
to conﬁrm that HUA treatment was inhibiting cell-cycle
progression (Figure 2A and B) and this resulted in a very sub-
stantial decrease (.50-fold, n ¼ 5) in the number of mitotic
cells (Figure 2A–C). Moreover, phH3-expressing cells were
substantially decreased even in internal embryonic tissues
demonstrating penetration of the HUA (Figure 2D vs. E).
phH3 cells in the linear heart-tube at stage-33/34, which
were already at a low level (Figure 1C), were barely detect-
able in sections of HUA-treated embryos at stage-33/34
(Figure 2D0 vs. E0).
ISH for markers of cardiac differentiation, TIc and
Nkx2.10, were performed on cardiac plate-stage embryos
(Figure 2F–J) and these were scored according to area of
expression, i.e. size of the heart ﬁeld. Heart-ﬁeld size can
vary somewhat both between batches of embryos and
between embryos from the same batch of eggs so quantiﬁ-
cation of absolute heart size by area measurement does not
allow statistically meaningful comparison between exper-
iments. Hence, we adopted a blind-scoring method of 0 to
3, where 0 denotes no detectable heart and 3 denotes a
heart of maximal size for that stage of development
(Figure 4A–D and Supplementary material online, Figure S1D).
Although a small number of HUA-treated embryos had
smaller than average hearts, in the large majority of
embryos, the area of the heart ﬁeld was unchanged
(Figure 2K), indicating that, following gastrulation, cell pro-
liferation is not absolutely essential for differentiation of a
cardiac plate of normal size. Moreover, antibody staining
of the linear heart tube at stage-33/34 showed that the
expression of Tropomyosin was also generally minimally
affected (Figure 2D0 vs. E0), indicating that later events up
to linear heart-tube formation were not substantially per-
turbed. Therefore, in post gastrulation Xenopus embryos,
cardiac differentiation can occur in the absence of cell-cycle
progression.
3.3 Xic1 is expressed in the Xenopus embryonic
heart
We ﬁrst investigated whether the CDKI Xic1 is expressed at
the right time and in the right place to be playing a role in
cardiac development. To this end, we performed ISH on
embryos of increasing stage.
Starting at stage-27, a ventral view of the embryo reveals
a region of Xic1 expression posterior to the anterior placodes
and cement gland, in a position consistent with a low level
of expression in the developing heart (Figure 3A, arrow),
Figure 1 Division of embryonic cardiomyocytes. (A) Stage-33/34 embryo,
Tropomyosin (red) in the cardiac tube, phH3 (green), DNA in nuclei (Hoechst,
blue). Arrowhead: dividing cardiomyocyte (phH3 and Tropomyosin positive).
(B) Total number of Tropomyosin-positive cardiomyocytes at increasing
embryonic-stages (n   3 embryos/stage). (C) Percentage of dividing cardio-
myocytes (both phH3 and Tropomyosin positive) at increasing stages.
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(data not shown). By stage-31, these swimming tadpoles
are expressing Xic1 more intensely in the head, eye, and
myotome region, and additionally in the ventral heart
region just posterior to the cement gland
7,8 (data not
shown). Expression in this region is maintained at least
until stage-41 (Figure 3E, arrow).
To conﬁrm Xic1 is expressed in the heart itself and not
in overlying ectoderm, we took an RT–PCR approach.
Linear heart-tube formation in Xenopus is completed by
stage-32
18 and the tube can be dissected out as a discrete
entity from stage-33/34 onwards. We dissected hearts
from stage-33/4 to stage-42 embryos (Figure 3F) along
with tailbud tissue, where Xic1 is strongly expressed
8 as a
positive control, and RT–PCR was performed to detect Xic1
expression. Xic1 message is clearly detectable in the heart
and levels do not change dramatically from stages-33/4 to
stage-42 (Figure 3G). Therefore, Xic1 is expressed at the
right time and in the right place to play a role in cell-cycle
exit and differentiation of the Xenopus heart.
Figure 2 Cell division is not required for cardiomyocyte differentiation. Embryos stained for phH3 expression after incubation without (A) or with HUA (B) from
stage-13. (C) Percentage of phH3-positive cells in the epidermis are decreased after HUA treatment vs. untreated control (matched areas, n   3 separate
embryos +SD; *P , 0.001). Transverse sections of stage-33/34 embryos after incubation of embryos in normal media (D and D0) or media containing HUA (E
and E0), Tropomyosin expression (red), phH3 (green), and DNA in nuclei (Hoechst, blue);
§Myotome is also positively labelled by tropomyosin. Note: Stage-29/
30 embryos after control (F and H) or HUA (G and J) incubation showing TIc (F and G) or Nkx2.10 (H and J) expressions. (K) Heart size in control or HUA-incubated
embryos as measured by TIc and Nkx2.10 expression area (see Figure 4A–H for examples).
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heart
To investigate the effect of Xic1 overexpression, we injected
mRNA encoding either full-length Xic1 or deletion-
constructs encompassing the N- or C-terminal regions,
targeted to the developing heart region. Interestingly, injec-
tion of these constructs had no signiﬁcant effect on heart
formation (Supplementary material online, Figure S3).
As Xic1 is expressed in the developing heart, we also
investigated the effect of Xic1 depletion on heart formation
in Xenopus. Antisense morpholino-oligonucleotide (Mo)
injection blocks translation of Xic1 mRNA in Xenopus
embryos,
8 resulting in undetectable levels of the protein
(Supplementary material online, Figure S1C). Xic1Mo, or a
speciﬁc CTRMo, was targeted to the heart region by injec-
tion into two dorsal-vegetal blastomeres at the 8-cell
stage. Embryos were allowed to develop to stage-29/30,
when the extent of cardiac differentiation in embryos was
visualized as two symmetrical ﬂat plates expressing TIc
(Figure 4A–D) and/or Nkx2.10 (not shown), either side of
the ventral midline. The area of the cardiac plate was
scored blindly on a scale of 0 to 3, as described earlier.
Embryos were also observed at stage-33/34 (Figure 4E–H)
when the linear heart-tube has formed but before morpho-
logical looping has commenced.
Targeted injection of Xic1Mo resulted in a signiﬁcant
decrease in the size of the differentiating heart, as
indicated by expression of TIc, when compared to sibling-
uninjected embryos (e.g. Figure 1A–C and E–G, and
Supplementary material online, Figure S1D). Although dif-
ferentiated heart tissue was clearly diminished in Xic1
depleted embryos, nevertheless myocardial wall closure
commenced normally, since the linear heart-tube was
clearly visible at stage-33/4 (Supplementary material
online, Figure S1D). Following injection of Xic1Mo, 39% of
embryos exhibited a substantially reduced heart (0 or 1
based on TIc expression) whereas only 5% of CTRMo-injected
embryos exhibited a similar phenotype (Figure 4J). Interest-
ingly, we observed no difference in the heart rate of
stage-37/8 Xic1 depleted embryos (49.6+4.8, n ¼ 16),
where hearts were visible, compared to stage matched
uninjected (50.1+3.9, n ¼ 15) or CTRMo-injected (50.3+
4.0, n ¼ 19) embryos. Thus, upon depletion of Xic1, late-
stage embryos still generally retain a broadly functional,
albeit smaller, hearts. However, we occasionally observed
alive embryos without a detectable heart beat, presumably
corresponding to embryos which exhibited no expression
of cardiac differentiation markers in the ISH studies
(scored as ‘0’).
To demonstrate speciﬁcity for loss of Xic1 protein, we
co-injected Xic1Mo with mRNA coding for Xic1, which
could not be targeted by the morpholino (Supplementary
material online, Figure S1A and B). Co-injection of CTRMo
with this Xic1 RNA had only a very small effect on heart
Figure 3 Xic1 is expressed in the differentiating heart. In situ hybridization to detect Xic1 in ventral or lateral view (A–E) of stage 27–41 embryos. Xic1 is weakly
expressed in the hearts of embryos from stage-27 onwards (arrows). Picture B was taken following clearing embryo with Benzyl-benzoate:Benzyl-alcohol. (G)R T–
PCR conﬁrming expression of Xic1 transcript in the dissected hearts (F) of stages-33/4 to -42.
M. Movassagh and A. Philpott 440Figure 4 Xic1 is required for heart formation. TIc expression in Xic1Mo injected embryos at stage-29/30 (A–D) and stage-33/34 (E–H), demonstrating the range
of cardiac phenotypes from normal expression of TIc (D and H, score ¼ 3) to no expression of TIc (A and E, score ¼ 0). (J) Graph summarizing the percentage of
stage-29/30 embryos with hearts of sizes 0 to 3, as assayed by TIc expression, following injection with 20 ng of CTRMo or Xic1Mo and rescued by co-injection with
Xic1mRNA (30 pg). n ¼ 58–130 embryos per injection. Transverse sections of stage-33/34 embryos, after injection with CTRMo (K and K0) or Xic1Mo (L and L0),
Tropomyosin (red), phH3 (green), DNA in nuclei (Hoechst, blue).
§Myotome is also positively labelled by tropomyosin. (M) Total number of cardiomyocytes (blue or
red) and the proportion of phH3 cardiomyocytes (green) in ﬁve separate stage-33/34 embryos, injected with either CTRMo or Xic1Mo. (N) Average total number
of cardiomyocytes (blue or red), and the number of dividing cardiomyocytes (green) from embryos shown in graph M (*P ¼ 0.022, n ¼ 5).
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material online, Figure S3B), where hearts remained predo-
minantly size 3 (Figure 4J). However, the reduction in heart
size seen after Xic1Mo injection was signiﬁcantly rescued by
co-injection with Xic1 mRNA; the percentage of embryos
with a severely reduced heart (score of 0 or 1) dropped by
half, from 39 to 19%, while the number of size 3 hearts
rose from 24 to 57% (Figure 4J). Therefore, Xic1 is required
for heart formation in Xenopus.
CTRMo (Figure 4K) or Xic1Mo (Figure 4L) injected embryos
were sectioned, and stained for Tropomyosin and phH3. As
we saw by ISH for TIc, we observed a range of phenotypes
(Supplementary material online, Figure S4). The majority
of Xic1Mo injected embryos showed a marked reduction in
the total number of differentiated cardiomyocytes when
compared to CTRMo (Figure 4M). Indeed in some embryos,
few if any, differentiated cardiomyocytes could be detected
in any of the sections (Figure 4L0). On average, we observed
a 50% reduction in total number of cardiomyocytes in sec-
tions from Xic1Mo injected embryos (310+175) when com-
pared to sections from CTRMo injected embryos (639+192)
(n ¼ 5, P ¼ 0.022) (Figure 4N). Depletion Xic1 did not result
in a detectable induction of apoptosis, as no increase TUNEL
positive nuclei following injection of Xic1Mo (16+22, n ¼ 5)
was seen, compared to uninjected (30+15, n ¼ 5) or
CTRMo injected (46+13, n ¼ 5) embryos.
Upon injection of Xic1Mo, we did not observe a signiﬁ-
cantly change in the number of phH3-expressing cells in
the remaining Tropomyosin-positive tissue (1.4+0.6%, per-
centage of phH3 positive cardiomyocytes, n ¼ 5), when
compared to sections from CTRMo injected embryos
(1.9+0.9%) (Figure 4N), or in the surrounding area
(Figure 4L0 and data not shown). These results suggest that
Xic1 is probably not the central regulator of cell-cycle exit
in this tissue at this time, but it may be present to fulﬁl
an alternative function in differentiation.
3.5 The cardiac differentiation function of Xic1 is
located N-terminally but is distinct from its CDK
kinase inhibitory activity
It has previously been reported that Xic1 is required for
differentiation of primary neurons and myotomal muscle,
independent of its ability to arrest the cell cycle, and this
function is localized to the N-terminus of Xic1.
7,8 Hence,
we wished to determine whether it is the cell-cycle inhibi-
tory function of Xic1 that is required for cardiac differen-
tiation, or whether an additional function of Xic1 beyond
cell-cycle regulation is required. To this end, we attempted
rescue of the reduced cardiac phenotype seen after injec-
tion of Xic1Mo using Xic1 mutant constructs.
Embryos were injected with CTRMo or Xic1Mo, either with
or without mRNA for non-targeted Xic1-FL (Supplementary
material online, Figure S1A and B) or truncation mutants
of Xic1 (Supplementary material online, Figure S2). Follow-
ing targeted injections, embryos were allowed to develop to
the cardiac plate stage, stage-29/30, and Nkx2.10 and TIc
expression was determined. As expected, the majority of
embryos injected with Xic1Mo (Figure 5C, J, and P) demon-
strated a signiﬁcant decrease in the expression of these
markers of cardiac differentiation compared to uninjected
(Figure 5A and H) and CTRMo (Figure 5B and I) injected con-
trols (Figure 5T). This Xic1Mo-induced cardiac phenotype
could be effectively rescued by co-injection with either
FL-Xic1 (Figure 5D, K, and Q) or NT-Xic1 (Figure 5E and L),
where the percentage of embryos with size 3 hearts rose
from 14 to 54% and 41%, respectively (Figure 5T). Interest-
ingly, Xic1(35–96), which can inhibit overall CDK-kinase
activity, has only a small rescuing ability (Figure 5G, N,
and T) while the C-terminus of Xic1 shows no rescuing
ability (Figure 5F, M, and T). These results indicate that
requirement for Xic1 in heart formation goes beyond its
ability to control cell-cycle progression since both the
N-terminus and C-terminus are able to inhibit the cell
cycle, yet only the N-terminus can rescue cardiac
differentiation.
Since our results indicted that the N-terminal segment of
Xic1, which encompasses the Cyclin:CDK binding domain
(Supplementary material online, Figure S2), is important
for its role in cardiac differentiation, we investigated
whether binding to cyclins and CDKs is required for Xic1 to
promote cardiac differentiation. The residues within Xic1
which are critical for cyclin and CDK bindings have been pre-
viously identiﬁed by mutagenesis and a Xic1 construct with
mutations within both the cyclin-binding domain (R33A and
L35A) and CDK-binding domains (F65A and F67A) has been
described, which is unable to bind to CDK2 and Cyclin E,
19
the predominant CDK/cyclin pair at this stage in develop-
ment. Hence, we constructed a Xic1 mutant, Xic1
CK-, engin-
eered to prevent targeting by Xic1Mo, and performed rescue
experiments by co-injection with Xic1Mo (Supplementary
material online, Figure S2). Interestingly, this mutant still
had the ability to rescue the loss of cardiac differentiation
observed following injection of Xic1 Mo (Figure 5R and T).
3.6 Xic1 depletion inhibits later stages of
cardiomyocyte differentiation
Our results indicate that Xic1 is required for cardiomyocyte
differentiation and this effect is detectable by stage-29/30.
However, we wished to determine whether Xic1 is required
early in speciﬁcation of cardiomyocytes or later, during car-
diomyocyte differentiation. Thus, ﬁrst we investigated the
expression of Xic1 transcripts in the presumptive cardiac
ﬁeld during early stages of development and compared its
expression to that of Nkx2.5.
20 In our hands, Nkx2.5 is ﬁrst
detected at stage-15 (Figure 6A) and in agreement with pre-
vious reports, its expression, although somewhat diffuse, is
localized to the ventral region of Xenopus embryos.
20 In con-
trast, at the same stages of development, the expression of
Xic1 transcript is predominantly localized dorsally although
a low level of anterior-ventral expression can be seen
(Figure 6B, stage-16/7 and stage-18).
Nkx2.5 expression can be seen as a ventral crescent span-
ning the midline by stage-17, the presumptive cardiac ﬁeld,
with levels increasing through to stage-21 (Figure 6A and C).
After targeted injection of Xic1Mo or CTRMo, Nkx2.5
expression was not signiﬁcantly altered, indicating that
Xic1 is not required for formation of the cardiac ﬁeld at
early stages of development (Figure 6).
Loss of Xic1 has a marked effect at later stages of
development, resulting in defective cardiac differentiation
(Figure 4). To determine where in the cardiomyocyte
differentiation program Xic1 is required, Xic1Mo or
CTRMo-injected embryos were harvested at increasing
stages of development. cDNA was prepared and assayed by
M. Movassagh and A. Philpott 442Figure 5 The requirement for Xic1 in cardiomyocyte differentiation is distinct from its ability to arrest the cell cycle. Stage-29/30 embryos either uninjected
(A and H) or injected with CTRMo (B and I), Xic1Mo (C, J, and P), or Xic1Mo plus FL-Xic1 (30 pg) (D, K, and Q), NT-Xic1 (15 pg) (E and L), CT-Xic1 (30 pg) (F and M),
Xic1(35–96) (30 pg) (G and N), Xic1
CK- (R), or CTRMo plus Xic1
CK- (S) detecting either Nkx2.10 (A–G) or TIc (H–S). (T) Percentage of stage-29/30 embryos with
heart sizes 1–3 (cf. Figure 4) following injection with Mo and mRNA combinations as described. n ¼ 26–53 embryos/treatment group.
p27Xic1 is required for Xenopus cardiac differentiation 443semi-quantitative RT–PCR for expression of TIc and MHCa,
late markers of cardiomyocyte differentiation. While at
stages-24 and -26, the effect of Xic1Mo on TIc was unclear,
by stage-27/28 the expression of TIc was reduced in the
Xic1-depleted embryos and this persisted up to stage-33/
34 (Figure 6D). MHCa was undetectable at earlier stages
but by stage-27/28 when levels were increasing, MHCa
expression was absent in embryos injected with Xic1Mo,
Figure 6 Xic1 is required for late stages of cardiomyocyte differentiation. Expression of Nkx2.5 (A) or Xic1 (B)b yin situ hybridization at described stages.
Nkx2.5 staining is largely localized to the ventral side of embryos in the cardiac crescent (A, white arrows). In contrast, Xic1 expression is predominantly
dorsal (B, Dorsal view, black arrows) and only weakly detected at the ventral side (B, ventral view, black star-arrowhead). (C) Xic1Mo does not affect the
cardiac ﬁeld as measured by Nkx2.5 expression at stages-17, -19 and -21 of development. (D)R T –PCR from uninjected embryos or embryos injected with
either CTRMo or Xic1Mo to detect expression of TIc and MHCa with ODC as loading control, stages as described. (E) Quantitative RT–PCR demonstrating the rela-
tive expression of xMLC1v in embryos described in (D), following normalization against xODC.
M. Movassagh and A. Philpott 444through to stage-33/34 (Figure 6D). These results conﬁrm
that Xic1 is required at these later stages when cardiomyo-
cyte differentiation occurs. xTIc and xMHCa are both
expressed in the primary heart-tube, throughout the
embryonic myocardium at later stages of development. In
contrast, MLC1v is found in the primary heart-tube and
later, only speciﬁcally in the ventricles but not in the
atria.
21 The quantitative-PCR analysis shows that MLC1v is
also downregulated after Xic1 depletion (Figure 6E), demon-
strating that at least the primary heart ﬁeld is affected by
the loss of Xic1.
4. Discussion
We aimed to determine the extent to which cell-cycle
progression is required for either the speciﬁcation of the
presumptive cardiac ﬁeld or for differentiation of Xenopus
cardiomyocytes. We found mitotic phH3-expressing cells
co-expressing the cardiac differentiation marker Tropomyo-
sin (Figure 1A), suggesting that at least up to stage-41 of
Xenopus embryonic development, differentiating cardio-
myocytes can still undergo active cell division. These obser-
vations are in agreement with early reports of observed
cytokinesis in dividing embryonic rat and mouse cardiomyo-
cytes which are gradually diminished at early postnatal
stage.
2 We observed an increase in the total number of
cardiomyocytes in the developing Xenopus heart resulting
in a four-fold increase from stage-29/30 to stage 41
(Figure 1B). The total number of cardiomyocytes doubled
from stage-32 to stage-37/8, consistent with a previous
report in the same species by Goetz et al.
15 and with the
morphological changes that occur as the linear heart-tube
undergoes right-hand looping. Indeed, a small percentage
of cells remain in cycle even as late as stage-41
(Figure 1C). Interestingly, at stages-31 and -32 we observed
a statistically signiﬁcant increase in the percentage cardio-
myocytes that were mitotic (Figure 1C). These ﬁndings are
consistent with the reported increase in the length of
linear heart-tube in Xenopus embryo, where proliferation
may be a prerequisite for the looping to commence.
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It has been proposed that cardiomyocytes have an intrin-
sic program of cell division that dictates the number of cell
cycles before differentiation can occur.
22 However, it is not
clear whether cell division per se is required for cardiac
speciﬁcation and differentiation, as is the case in other
cell types such as cortical neurons.
23 Neither is it clear
whether, in Xenopus, cell division of cardiac precursors is
actually required for formation of a cardiac plate of
normal size. Therefore, we addressed these questions by
looking at speciﬁcation and differentiation of the cardiac
plate after the cell cycle had been substantially inhibited
by incubation of embryos in HUA. Since cell-fate determi-
nation and speciﬁcation of cardiogenic precursor cells of
the primary heart ﬁeld is thought to occur during gastrula-
tion,
24 cell-cycle arrest in our embryos by incubation in
HUA from stage-13 should not interfere with this process.
Tropomyosin (Figure 2D and E), TIc (Figure 2F and G), and
Nkx2.10 (Figure 2H and J) expression was minimally
affected by HUA treatment, indicating that the ﬁnal
cardiac plate area is not substantially determined by pro-
liferation of a small number of committed cardiac progeni-
tors post-gastrulation, and indeed cell proliferation beyond
gastrulation is not absolutely required for speciﬁcation or
differentiation of cardiomyocytes in the cardiac plate
(Figure 2). Our results are consistent with observations in
chick embryos, where Soufan et al.
25 demonstrated that a
four-fold increase in the length of the primary heart-tube
had occurred when the tube hardly displayed any prolifera-
tive activity, as quantiﬁed by a very low phH3-labelling
index. These authors demonstrated that the majority of
the growth in the linear heart-tube was attributed to the
‘recruitment’ of precursor cells to the linear heart-tube.
25
Although Xenopus has three CDKIs,
12,26 Xic1 is the predomi-
nant CDKI expressed at early developmental stages, sharing
homology with all members of the mammalian CIP/KIP
family.
27 We see that Xic1 is expressed in developing heart
(Figure 3). The timing of expression of Xic1 in cardiomyocytes
at late tail-bud stages of development ﬁts well with a role in
controlling cardiomyocyte differentiation rather than a role
in earlier speciﬁcation. We explored this further. We
investigated whether Xic1 is required for formation of the
Xenopus heart, and if so, whether it acted at an early stage
of speciﬁcation or later stages in cardiomyocyte differen-
tiation. Previous reports demonstrate that overexpression of
Xic1 results in both an increase in the number of primary
neurons and an expanded myotome.
7,8 However, we did not
observe any substantial alteration in Xenopus heart size
following overexpression of Xic1 or Xic1 mutants thereof
(Supplementary material online, Figure S3B).
Why does overexpression of Xic1 expand the myotome but
not the heart? Myotomal muscle can be induced by a single
myogenic factor, MyoD. We have previously demonstrated
that both MyoD and Xic1 must be above threshold levels to
promote myotomal muscle differentiation.
8 However,
unlike the myotome, cardiomyocyte differentiation involves
numerous cardiogenic transcription factors acting in
concert. Therefore, even though Xic1 may be required for
cardiomyocyte differentiation, elevation of Xic1 levels
alone may be insufﬁcient to promote further cardiogenesis,
leading to a bigger heart.
To determine whether Xic1 is required for heart forma-
tion, we inhibited Xic1 using Xic1Mo. Loss of Xic1 resulted
in a substantial decrease in the area of the cardiac plate
expressing Nkx2.10 (Figure 5C), TIc (Figure 5J and P), and
also cardiac-actin and MHCa (not shown) at stage-29/30,
with a corresponding decrease in the size of the heart-
tube at stage-33/34 (Figure 4K and L, and Supplementary
material online, Figure S1D). Moreover, the depletion of
Xic1 resulted in a statistically signiﬁcant decrease in the
number of differentiated cardiomyocytes expressing Tropo-
myosin at stage-33/34 (Figure 4M and N). The loss of differ-
entiated cardiomyocytes was speciﬁcally due to loss of Xic1,
as this phenotype could be rescued to a large extent by
co-injection of Xic1 mRNA (Figure 4J, 5D, K, and T).
At neurula stages, Xic1 is not strongly expressed in the
cardiac ﬁeld (Figure 6B), suggesting that Xic1 is unlikely to
play a role in the early stages of cardiac development.
However, its later expression in the anterio-ventral region
of tailbud stage embryos where cardiac differentiation
occurs (Figure 3A–E) indicates that Xic1 may function in
later stages of cardiomyocyte differentiation. Loss of Xic1
had no effect on expression of Nkx2.5 at early stages, indicat-
ing that Xic1 levels do not inﬂuence the speciﬁcation of the
presumptive cardiac ﬁeld (Figure 6C). However, expression
of later markers of cardiac differentiation were reduced by
Xic1Mo (Figures 4–6). As Xic1 depletion also resulted in
p27Xic1 is required for Xenopus cardiac differentiation 445diminishing expression of xMLc1v, this suggests that Xic1 is
needed for the differentiation of the primary heart-tube. It
would be interesting to know if Xic1 also affects the differen-
tiation of the artrioventricular canal, the atrium and/or the
secondary heart ﬁeld and septation of atrium which occurs
at stages-44 and beyond in Xenopus. However, this may not
be possible in Xenopus embryos using the same strategy,
as these events occur at stages beyond those at which
morpholinos are likely to be effective.
To determine whether Xic1’s role in differentiation is
solely to promote cell-cycle exit in cardiomyocytes, we
rescued Xic1Mo-induced loss of cardiac differentiation with
different Xic1 deletion constructs, which all have the
ability to inhibit cell-cycle progression (Supplementary
material online, Figure S3A) but by different mechanisms.
FL-Xic1 (Figure 5D, K, Q, and T) and NT-Xic1 (Figure 5E, L,
and T) both inhibit CDK-kinase activity and can rescue
cardiomyocyte differentiation. In contrast CT-Xic1, which
inhibits the cell cycle by binding PCNA, cannot rescue the
loss of differentiated heart tissue seen with Xic1Mo
(Figure 5F, M, and T). Xic1(35–96) can block the cell cycle
and inhibit the majority of CDK kinase activity but it
cannot promote neurogenesis or myogenesis in the early
tadpole.
7,8 However, Xic1(35–96) can partially rescue the
loss of cardiomyocyte differentiation, albeit more weakly
that FL-Xic1 and NT-Xic1 constructs (Figure 5T).
Our results suggest that Xic1 is required for late stages of
cardiomyocyte differentiation. Is this because it must drive
cells to exit the cell cycle to terminally differentiate? Our
evidence argues against this possibility: ﬁrst, Xenopus cardi-
omyocytes can still divide even when expressing markers of
terminal differentiation (Figure 1 and Goetz et al.
15), indi-
cating that cell-cycle exit is not an absolute prerequisite
for this process. Second, the C-terminus of Xic1 is able to
inhibit the cell cycle (Supplementary material online,
Figure S3A) yet it cannot rescue the loss of heart seen
when endogenous Xic1 is lost (Figure 6F, M, and T). Third,
we see no signiﬁcant difference in the total number of
phH3 expressing mitotic cardiomyocytes following injection
of Xic1Mo (1.4+0.6%), when compared to sections from
CTRMo injected embryos (1.9+0.9%) (Figure 4N), indicat-
ing that Xic1 does not regulate cell-cycle exit in this tissue.
However, our results did not rule out the possibility that
the ability of Xic1 to promote cardiac differentiation might
be due to the ability of Xic1 to bind to and inhibit Cyclin/
CDK2 activity. FL-Xic1, NT-Xic1 and Xic1(35–96) all share
the ability to inhibit overall CDK2 kinase activity and all
are able to restore heart differentiation to a greater or
lesser extent when co-injected with Xic1Mo. Indeed,
Xic1(35–96) produces a less efﬁcient rescue that FL-Xic1
and NT-Xic1 (Figure 5T), and this might be because it is
fully able to inhibit Cyclin E/CDK2, the predominant CDK2
kinase at these stages, but it has a reduced ability to
inhibit Cyclin A2/CDK2.
28
Thus, to address this possibility, we performed rescue
experiments using a Xic1 mutant (Xic1
CK-) harbouring
mutations within the cyclin (R33A, L35A) and CDK (F65A,
F67A) binding domains (Supplementary material online,
Figure S2). It had previously been reported that these
mutations abolish the binding ability of Xic1 to CDK2
and cyclin E.
19 Xic1
CK- is effective at rescuing the loss of
cardiac differentiation seen with Xic1Mo injection
(Figure 5R, T). This indicates that inhibition of cyclin
E/CDK2, the predominant cyclin/CDK pair at this stage, is
not essential for Xic1’s role in cardiac differentiation.
Nevertheless, we cannot rule out the possibility that the
Xic1
CK- mutant may retain some ability to bind to and
inhibit the activity of cyclin A2/CDK2 or another cyclin/
CDK pair, which regulates cardiomyocyte differentiation.
However, we would note that cyclin A2 expression is essen-
tially undetectable in the Xenopus heart up to stage-33/4 of
development.
29
Loss of the mammalian CDKI, p27
Kip1, in mice leads to
bigger organs, including the heart, demonstrated to be
due to an increase in the total cell number.
30 However,
this may only occur in species where cell proliferation of
precursors contributes substantially to growth of the
heart, and this appears not to be the case in Xenopus
(Figure 2D–K), and redundancy may allow other CDKIs to
perform essential differentiation functions in mammals fol-
lowing knockout of a single CDKI.
So how is Xic1 playing a role in cardiac differentiation, if
not via its cell-cycle regulatory function? Interestingly, the
mammalian CDKI p57
Kip2 has been shown to physically interact
with the myogenic factor MyoD, further stabilizing and
increasing its half-life.
31 It is possible that Xic1 might be
binding to one of the many transcription factors that drive
cardiac differentiation, leading to its stabilization and thus
further promoting cardiogenesis, although, we have been
unable to demonstrate a physical interaction between
in vitro translated Xic1 and either Nkx2.5, Tbx5, GATA4, or
Myocardin proteins by immunoprecipitation (data not shown).
In summary, here we provide evidence that a CDKI plays
an important role in cardiac differentiation beyond its
ability to arrest the cell cycle. Currently, much is being
learned about the multi-functionality of CDK inhibitors,
and if we are to understand the versatility of these
molecules, it will be important to investigate CDKI function
in systems where effects on the cell cycling can be distin-
guished from other less obvious roles.
Supplementary material
Supplementary material is available at Cardiovascular
Research online.
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